Simeoni M, et al. - In this open-label, placebo-controlled intervention study (ProbiotiCKD), researchers assessed the efficacy of a novel probiotics administration protocol in a cohort of KDIGO chronic kidney disease (CKD) patients (n=28). They assessed gut microbiota metabolism at baseline and after a randomly assigned treatment with probiotics (sequentially administered different complexes of high concentration and stable probiotics) or placebo. The presence of an intestinal mixed dysbiosis, even in early CKD stage, was evident in this first intervention study. Findings also revealed that such a dysbiosis could be effectively corrected by the novel mode of administration of high-quality probiotics. Moreover, the intestinal dysbiosis correction was found to be related to improved C-reactive protein, iron status, intact parathormone and β2-microglobulin only in the treated group.